MangoRx launches oral Tirzepatide weight loss tablet 'TRIM' at $399/month

MANGOCEUTICALS, INC.

TRIM is a compounded oral dissolvable Tirzepatide tablet priced at $399 per month.
Tirzepatide is a dual GIP/GLP-1 receptor agonist; clinical trials showed up to 20% weight loss in 72 weeks.
TRIM complements existing oral Semaglutide product (SLIM), offering two GLP-1 options.
Global GLP-1 market projected to grow from $49.3B (2024) to $157.5B by 2035 per Roots Analysis.
Available by prescription via MangoRx telemedicine platform; targets non-injectable weight loss demand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.